Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.

NCT02356458 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT02356458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02356458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Lead sponsor
Swiss Cancer Institute
Phase
Phase 1/2
Overall status
Terminated
Start date
August 31, 2015
Completion date
March 30, 2021
Enrollment
58 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma